title: Bronchodilator response to adrenergic beta2-agonists: relationship to symptoms in an adult community.
abstract: BACKGROUND
  Wheeze and chest tightness has traditionally been associated with enhanced bronchial responsiveness. However, no community studies are available on the associations between bronchodilator response and respiratory symptoms among adults.
  
  
  OBJECTIVE
  To examine how respiratory symptoms predict bronchodilator response.
  
  
  METHODS
  An age and gender stratified random sample of all adults aged 47-48 and 71-73 years in Bergen, Norway, were invited. The 3506 participants (69%) filled in questionnaires including nine symptoms and performed bronchodilator reversibility tests. Subjects without current anti-asthmatic medication performing acceptable reversibility tests were included in the analyses (n=3088).
  
  
  RESULTS
  A reversibility with FEV(1) increase 12% and 200 ml was obtained in 2% of middle-aged and 4% of elderly subjects (p=0.001). In multiple linear regression analysis bronchodilatation was positively associated with wheezing without cold (FEV(1) increase of 1.5%, 95% CI: (0.9, 2.2)% in all participants and 31 ml, 95% CI: (1, 61)ml in men only) and dyspnoea climbing two flights of stairs (0.9%, 95% CI: (0.5,1.4)% and 12 ml, 95% CI: (1,23)ml). Chronic cough predicted the response negatively (-0.7%, 95% CI: (-1.3,-0.1)% and -17 ml, 95% CI: (-32,-2)ml). In multiple logistic regression analysis morning cough predicted an FEV(1) increase 12% and 200 ml (OR: 1.8, 95% CI: (1.1,2.8)).
  
  
  CONCLUSIONS
  A small fraction of adults in a general population has bronchodilatation after salbutamol inhalation. "Wheezing without cold", "dyspnoea climbing two flights of stairs", and "morning cough" predict an increased bronchodilator response among subjects without current anti-asthmatic medications.
authors.affiliation: Section for Thoracic Medicine, Institute of Medicine, University of Bergen, 5021 Bergen, Norway. sverre.lehmann@helse-bergen.no
authors.forename: Sverre
authors.initials: S
authors.lastname: Lehmann
authors.forename: Per Sigvald
authors.initials: PS
authors.lastname: Bakke
authors.forename: Geir Egil
authors.initials: GE
authors.lastname: Eide
authors.forename: Amund
authors.initials: A
authors.lastname: Gulsvik
mesh_terms: D000318:Adrenergic beta-Agonists; D000367:Age Factors; D000368:Aged; D000420:Albuterol / Q000627:therapeutic use; D015992:Body Mass Index; D016084:Bronchoconstriction / Q000187:drug effects; D001993:Bronchodilator Agents; D003371:Cough / Q000209:etiology / Q000503:physiopathology; D004417:Dyspnea / Q000209:etiology / Q000503:physiopathology; D005260:Female; D005541:Forced Expiratory Volume / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D012120:Respiration Disorders / Q000175:diagnosis* / Q000503:physiopathology; D012135:Respiratory Sounds / Q000187:drug effects; D014797:Vital Capacity / Q000187:drug effects
chemical_list: D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D000420:Albuterol